HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parlux Q2

This article was originally published in The Rose Sheet

Executive Summary

Excluding impact of prior-year litigation, net income during the second quarter (ended Sept. 30) increased 122.5% to $1.4 mil., attributable largely to extensions of existing brands, fragrance marketer announces Nov. 13. Including prior-year pretax income of $4 mil. related to the settlement, net income decreased 55%. Net sales advanced 1.4% to $18.3 mil., impacted by sale of the Animale and Fred Hayman brands. However, the divestiture of those brands allowed the company flexibility to seek new opportunities, such as recent agreement to distribute GUESS? fragrances, firm points out (1"The Rose Sheet" Nov. 10, 2003, p. 4)...

You may also be interested in...



Guess? Fragrances Will Be Reintroduced By Parlux In 2005

Fragrance marketer Parlux will launch Guess? scents in over 1,000 U.S. specialty store doors and all freestanding Guess boutiques in early 2005, Parlux VP Marketing Kathleen Galvin said

ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market

Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel